52North Raises £3.2M Seed Led by Macmillan Cancer Support for At-Home Diagnostics

52North Raises £3.2M Seed Round

52North, a University of Cambridge spin-out, has raised £3.2 million in Seed funding. The round is dated September 29, 2026, and was led by Macmillan Cancer Support.

What the Company Does

52North has developed the Aster biomarker detection platform, built to move diagnostic testing out of hospital labs and into patients' homes.

Its lead product, Neutrocheck, is a rapid finger-prick blood test that lets chemotherapy patients be triaged remotely for neutropenic sepsis — a life-threatening complication that drives tens of thousands of UK emergency hospital visits each year.

The Clinical Problem

Neutropenic sepsis is a serious risk for chemotherapy patients, whose immune systems are compromised during treatment. When symptoms emerge, the default response is often an emergency department visit, contributing to the tens of thousands of UK emergency hospital visits the company cites each year.

Neutrocheck is designed to change that pathway by enabling remote triage through a finger-prick blood test, potentially allowing patients to be assessed without an in-person hospital visit.

Market Launch Preparation

Based in Cambridge, 52North is preparing Neutrocheck for its UK market launch. The company has backing from a syndicate of investors spanning cancer research, academia, healthcare, and venture capital.

Investor Syndicate

The Seed round was led by Macmillan Cancer Support. Additional investors include:

• Cancer Research Horizons
• University of Cambridge
• Macmillan Cancer Support
• OKG Capital
• Hargreave Hale AIM VCT
• Cedars Sinai Intellectual Property Company

The participation of Macmillan Cancer Support as lead, alongside Cancer Research Horizons and the University of Cambridge, reflects the company's roots in both academic research and the UK cancer-care ecosystem.

Funding Summary

• Company: 52North
• Round: Seed
• Amount: £3,200,000 GBP
• Date: September 29, 2026
• Lead investor: Macmillan Cancer Support
• Additional investors: Cancer Research Horizons, University of Cambridge, OKG Capital, Hargreave Hale AIM VCT, Cedars Sinai Intellectual Property Company
• Headquarters: Cambridge, United Kingdom
• Origin: University of Cambridge spin-out

What to Watch

With the Seed round closed, 52North's near-term focus is the UK market launch of Neutrocheck. The company's broader Aster biomarker detection platform suggests a pipeline beyond a single test, with the goal of shifting diagnostic testing from hospital labs toward patients' homes.